polymorphism concerning substances like primaquine or isoniazid, which are recent laboratory products and to which human populations have not been previously exposed? I think the answer must be that these genetical equilibria have not been established by the actions of the drugs which reveal their existence, but by other different selective agencies.
The quest for selective agencies, which might be responsible for such pharmacological diversity is hampered by many difficulties, most of all by the impossibility of direct demonstration and by the rapid and accelerating changes of human environment during historical times. In many cases one must guess at the effects of past conditions of nutrition, diseases and mating systems which do not at present prevail. Nevertheless a few tentative inferences can be drawn and these can sometimes be supported by additional evidence. It has for instance been found (Harris & Whittaker 1961 ) that the atypical pseudocholinesterase discovered through the application of muscle relaxants withstands inhibition by a substance in potato extracts, possibly solanin, better than the normal enzyme. Thus the genes responsible for different degrees and modes of esterase acetylation might be maintained in equilibrium by noxious substances, which commonly occur in natural food.
The G-6-PD deficiency gene not only produces an increased sensitivity to primaquine and other antimalarials and drugs which are of recent synthesis and application but probably also confers some protection against malaria (Adinolfi et al. 1963 ) which is of long standing in the old world. This complex situation is in addition complicated by the fact that the G-6-PD deficiency is also the cause of favism, occasionally a fatal hemolytic disease in certain Mediterranean areas caused by the eating of raw broad beans and known since classical antiquity, and which possibly was the cause for the prohibition of bean eating by the Pythagoreans.
The way in which the introduction of a new class of drugsthe barbituratescan reveal a widespread but largely hidden genetical polymorphism has been shown in family studies of white South Africans by Dean & Barnes (1955) ; here a dominant gene predisposed to greatly varying forms of porphyria.
'Tasters' and 'nontasters' for phenylthiocarbamide (Harris & Kalmus 1949) may show different metabolic responses to goitrogenic substances of the N-C= S class, some of which occur in vegetables of the cabbage family and may also be ingested with the milk from cows fed on kale. In any case 'tasters' and 'nontasters' show differences in the incidence of several thyroid diseases (Kalmus 1963) .
The dextran sensitivity of rats promises to widen the pharmacogenetical field for behavioural and possibly even social studies. It has been shown ) that the anaphylactoid reaction produced in most Norwegian rats by injection of dextran or egg white is suppressed in a minority by a recessive autosomal gene dx, which occurs at high frequency in many laboratory stocks and also in wild populations. Several pharmacological and metabolic consequences of these differences have been described, but possibly most interesting is a greatly increased resistance of the dextran-insensitive rats to traumatic shock, tourniquet injury (Gecse et al. 1964 ) and to heat shock. Considering that rats have been observed (Barnett 1963) to die from social stress (aggression), a hereditary generalized increase in resistance to stresses might be of considerable survival value.
It would appear that all the better-analysed instances of pharmacogenetical diversity are in fact enzyme polymorphisms and thus are only special instances of a much more general situation (Harris 1966) . That they are being discovered in increasing numbers due to the testing of new drugs both in laboratory animals and in patients demonstrates the biochemical specificity of modern drugs. There are two distinct cholinesterases: acetylcholinesterase, responsible for acetylcholine hydrolysis at the neuromuscular junction, and the less specific enzyme, cholinesterase (acylcholineacylhydrolase). The latter enzyme is found in most human tissues including the plasma, but not the red cells, and its function is unknown.
Since 1952 suxamethonium has been frequently used as a muscle relaxant. This compound is chemically similar to acetylcholine and is hydrolysed by cholinesterase but not by acetylcholinesterase. Because of this rapid destruction the muscular paralysis and associated apncea usually last about two minutes. But a small number of individuals are hypersensitive and develop a dramatically prolonged apncea and paralysis lasting for several hours. In the majority this sensitivity is due to the presence of an inherited cholinesterase variant which produces a lowered enzyme activity in the plasma. Genetic studies show that these sensitive individuals are homozygous for an abnormal gene.
Kalow and his collaborators have shown that this low activity is due not to a decrease in the plasma concentration of the normal enzyme, but to its replacement by an abnormal cholinesterase called by Kalow the atypical variant (Kalow & Genest 1957 , Kalow & Staron 1957 ). This conclusion is based on a comparison of the kinetic properties of cholinesterase from a normal individual with that from a suxamethoniumsensitive patient, when two main differences are found:
(1) The atypical variant has a lowered activity against all the substrates tested (Davies et al. 1960) . The substrate concentration curves show a higher Michaelis constant for the cholinesterase from a suxamethonium-sensitive propositus than that from a normal person, and therefore indicate that the two enzymes are distinct. (2) The atypical enzyme is more resistant to the majority of cholinesterase inhibitors (Kalow & Davies 1958 ). An example of such an inhibitor is the local anmsthetic dibucaine (cinchocaine, Nupercaine).
At a concentration of 10-5 molar under standardized conditions dibucaine inhibits the normal enzyme by about 80 % and the atypical variant by less than 25 %. This was first described by Kalow & Genest (1957) who called the percentage inhibition produced by a 10-5 molar concentration of dibucaine the dibucaine number or DN. They showed that the use of this inhibitor also clearly differentiated the heterozygote who has a DN between 52 and 69, from the two types of homozygote. It is therefore possible to differentiate the three genotypes for this variant. Further proof that the two enzymes are distinct is given by their separation with column chromatography (Liddell, Lehmann, Davies & Sharih 1962) . This will only occur at a pH greater than 9-0; at lower pH values thereisno difference in mobility. The atypical variant is also present in the tissues of the affected individual (Liddell etal. 1963 ).
In Canadian, British and Greek populations the frequency is remarkably constant: hetero-zygotes comprise 3 8 % of the population giving a gene frequency of close to 0-02 (Kalow & Gunn 1958 , Kattamis et al. 1962 . Smaller surveys in Portugal and North Africa suggest a similar frequency. In South-West Germany the heterozygote frequency is slightly lower at 2-9 % (Goedde et al. 1963) . A survey by Szeinberg et al. (1966) in Israel has demonstrated a higher heterozygote frequency among Jews of non-European origin.
The highest frequency was 9 7y% in Jews from Iraq and Iran. At the moment we have no idea what factors determine the frequency of the gene for atypical cholinesterase in various populations.
The gene frequency of 0-019 in a British population suggests that the atypical homozygote would occur in 1: 2,800. A survey to check this prediction by dibucaine testing would obviously be prohibitively large. But one would also expect the incidence of suxamethonium apnoea due to this variant to occur once in 2,800 cases. A survey of the incidence in anesthesia that I carried out gives an approximate figure close to that predicted. Atypical cholinesterase is the commonest variant, but two other rare variants have been discovered which render the affected homozygote sensitive to suxamethonium.
The first of these was described by Harris & Whittaker (1961 . They discovered that sodium fluoride, like dibucaine, inhibits atypical cholinesterase less strongly than the normal enzyme. Thus a 5 x 10-5 molar concentration of sodium fluoride inhibits the normal enzyme by about 60%, the atypical enzyme by about 2500 and sera from heterozygotes by about 45 %. Harris & Whittaker called this inhibition the fluoride number or FN. When large numbers of sera were examined a few individuals were found whose serum dibucaine numbers were slightly lower and fluoride numbers markedly lower than expected. The genetic evidence showed that this was due to the presence of another cholinesterase variant. This variant, which appears to be an allele of the gene for the atypical enzyme, has a slightly lower dibucaine number and markedly lower fluoride number than normal. The homozygote for this variant is certainly rare. Only two such individuals have been described, both discovered because of suxamethonium sensitivity (Lehmann et al. 1963) .
A third variant determines the complete absence of enzyme activity (Liddell, Lehmann & Silk 1962) . The existence of this variant was suspected because of anomalies in the inheritance of a few families in which the atypical gene was segregating. In each case individuals appeared on dibucaine testing to be abnormal homozygotes while the values in their parents predicted that they were heterozygotes. This anomaly could be explained if the apparently normal parent was in 12 fact a heterozygote for the normal gene and a gene determining the absence of cholinesterase activity. This theory was supported by the fortunate discovery of an apparent homozygote for this silent gene: a Greek woman who developed a suxamethonium apnoea and whose serum contained no cholinesterase activity. This variant is also rare. A total of 11 cases in eight families have so far been described. Goedde and his colleagues, using a specialized and sensitive technique has shown that in two of these cases there is a slight cholinesterase activity, comprising only about 1 or 2% of that seen in a normal individual (Goedde et al. 1965) . It is not certain whether this is true of all the so-called 'silent' variants. I have examined 3 of these individuals by a technique which is capable of detecting an enzyme activity less than 0 5 % of the normal and have failed to find any evidence of enzyme activity. However, the technique was different from that described by Goedde et al. (1965) and one cannot exclude the possibility that some activity will be demonstrated by his sensitive method. Nevertheless it may be that these cases of the 'silent' gene contain two distinct groups, one with a complete absence of cholinesterase activity and a second with about 1% of the normal level.
A fourth variant has been discovered by Harris et al. (1962) using starch gel electrophoresis. They showed that, using starch gel electrophoresis at an acid or neutral pH, four bands of cholinesterase activity could be found in the normal individual. These bands were called Cl, 2, 3 and 4, the slowest band, C4, containing about 90% of the total activity. But in about 5% of an English population there is a fifth band, the C5 band, which is genetically determined (Harris, Hopkinson, Robson & Whittaker 1963) . In family studies this variant behaves as an autosomal dominant with partial penetrance. The C5 variant is quite different from the other cholinesterase variants. The affected individuals are not sensitive to suxamethonium, indeed their average cholinesterase level is higher than that of normals. Even more interesting is the fact that this variant is not an allele of the others (Harris, Robson, Glen-Bott & Thornton 1963) .
There appear, therefore, to be two non-allelic genes controlling cholinesterase production: the Ch. locus where the dibucaine-resistant, fluorideresistant and silent variants have been described; and the Ch2 locus producing the C5 variant recognized by starch gel electrophoresis.
For the geneticist, therefore, the cholinesterase variants are an interesting example of an enzyme with two genetic loci and multiple alleles. We have at the moment no idea why these variants are maintained at a relatively low frequency in the normal population. Indeed we have no knowledge of the normal function of this nonspecific cholinesterase. The occurrence of healthy individuals with a complete absence of enzyme activity certainly indicates that cholinesterase is of little physiological importance under normal conditions.
From the more practical viewpoint of the anesthetist, the relatively common dibucaineresistant variant is the most important. He can expect that about one patient in every 3,000 will show a marked sensitivity to suxamethonium. The incidence may be less in patients who are given a blood transfusion during or immediately before operation. We have seen one atypical homozygote who developed a 90 minute period of apneea during a minor operation. Two years previously she had had only a ten minute period of apncea during an orthopeedic operation in which she had been given a blood transfusion.
Cholinesterase is a very stable enzyme and is preserved well in freeze-dried plasma. A rapid transfusion of plasma may well be a specific treatment for suxamethonium apncea.
